Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Ultragenyx Pharmaceutical Inc. buy melinda

Start price
€57.91
23.06.17 / 50%
Target price
€76.67
20.07.17
Performance (%)
8.44%
End price
€62.80
20.07.17
Summary
This prediction ended on 20.07.17 with a price of €62.80. The BUY prediction by melinda finished with a performance of 8.44%. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Ultragenyx Pharmaceutical Inc. -5.314% -5.314% 0.513% -44.000%
iShares Core DAX® -3.033% 0.651% 12.268% 18.187%
iShares Nasdaq 100 -3.554% -3.007% 27.682% 47.279%
iShares Nikkei 225® -3.938% 1.935% 10.515% 10.489%
iShares S&P 500 -1.517% -0.602% 25.859% 45.572%

Comments by melinda for this prediction

In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Prediction Buy
Perf. (%) 8.44%
Target price 76.670
Change
Ends at 20.07.17

pharma



- Inc Ultragenyx Pharmaceutical .: Ultragenyx bietet regulatorischen Update auf burosumab (krn23) pharmazeutischen .Ultragenyx Inc. - nach der Vereinbarung Vorlage bla burosumab ist für die zweite Hälfte von 2017 geplant Die Ergebnisse vereinbart , dass blah kann nach verfügbaren klinischen eingereicht werden ...


Prediction Buy
Perf. (%) 8.44%
Target price 76.670
Change
Ends at 20.07.17

(Vom Mitglied beendet)

Stopped prediction by melinda for Ultragenyx Pharmaceutical Inc.

buy
Ultragenyx Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€73.50
25.08.20
€77.00
04.11.21
1.36%
05.11.21

buy
Ultragenyx Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€50.68
31.08.17
€63.14
26.12.17
-14.69%
26.12.17

buy
Ultragenyx Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€64.20
23.06.17
€85.00
20.07.17
8.44%
20.07.17

buy
Ultragenyx Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€68.19
05.01.17
€76.67
27.02.17
12.65%
27.02.17